Bluefin Merger Subsidiary, Inc. /
89bio
Roche subsidiary completes acquisition of 89bio




Source for the buyer and target: Roche Holdings, Inc.
For the buyer and target.
“Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Roche’s wholly owned subsidiary Bluefin Merger Subsidiary, Inc., has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of 89bio, Inc. (“89bio”, NASDAQ: ETNB) at a price of $14.50 per share in cash, plus a non-tradeable contingent value right (CVR) to receive certain milestone payments of up to an aggregate of $6.00 per share in cash.”
Published 30 Oct 2025
Open the sourceWhat happened
Bluefin Merger Subsidiary, Inc. completed its acquisition of 89bio, Inc. through a merger, following the tender offer for the company’s shares. [01]
The offer provided $14.50 per share in cash, plus a contingent value right for milestone payments of up to $6.00 per share. 89bio is a clinical-stage biopharmaceutical company developing therapies for liver and cardiometabolic diseases. [01]
Who is involved, and the source
Everything on this page comes from the source below, quoted word for word.
Advisers
Target
- Fairness opinion to the targetCenterviewSource: SEC filing, as of 1 Oct 2025
- Fairness opinion to the targetMoelisSource: SEC filing, as of 1 Oct 2025
- Fairness opinion to the targetTransactions, MoelisSource: SEC filing, as of 1 Oct 2025
Each adviser in its source's own words. An adviser's own announcement is labelled as one: it is not independent reporting. Advisers are not parties to the deal.
Roche subsidiary completes acquisition of 89bio
This document is the source for the companies, stage, figure and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly